Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind-placebo-controlled and Open-label-Sevelamer Hydrochloride-controlled, Dose-ranging Study for ASP1585 in Patients With Chronic Kidney Disease(CKD) and Hyperphosphatemia on Hemodialysis

NCT00505037 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00505037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00505037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind-placebo-controlled and Open-label-Sevelamer Hydrochloride-controlled, Dose-ranging Study for ASP1585 in Patients With Chronic Kidney Disease(CKD) and Hyperphosphatemia on Hemodialysis
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
September 30, 2008
Enrollment
156 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, hyperphosphatemia